Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer

This study has been terminated.
(data analysis showed insufficient drug efficacy)
Sponsor:
Information provided by (Responsible Party):
Suresh S. Ramalingam, Emory University
ClinicalTrials.gov Identifier:
NCT00406276
First received: November 17, 2006
Last updated: August 19, 2013
Last verified: August 2013
  Purpose

This is an open-label, single-arm, Phase I/II trial to determine the safety of RAD001 in combination with docetaxel and compare the efficacy of RAD001 plus docetaxel versus published Phase II and III reports of docetaxel alone in patients with recurrent NSCLC.


Condition Intervention Phase
Lung Cancer
Drug: RAD001
Drug: Docetaxel
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Emory University:

Primary Outcome Measures:
  • Number of Subjects Showing Partial Response and Stable Disease With the Combination of RAD001 and Docetaxel. [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]

    Partial response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LD.

    Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive disease (PD), taking as reference the smallest sum Longest diameter(LD) since treatment started.


  • Time to Progression:Time Period (in Months) From Study Entry Until Disease Progression, Death, or Last Date of Contact. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    Period from study entry until disease progression, death, or last date of contact.

    Progressive Disease: Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.



Enrollment: 28
Study Start Date: November 2006
Study Completion Date: February 2013
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RAD001+Docetaxel
RAD001 in combination with Docetaxel.
Drug: RAD001
RAD001 will be given at a dose of 5mg/day in combination with docetaxel
Drug: Docetaxel
In combination with RAD001

Detailed Description:

This is an open-label, single-arm, Phase I/II trial to determine the safety of RAD001 in combination with docetaxel and compare the efficacy of RAD001 plus docetaxel versus published Phase II and III reports of docetaxel alone in patients with recurrent NSCLC.

New agents and regimens are urgently needed for lung cancer treatment. With the development of novel agents and small molecules designed to curtail the aggressive aspects of this disease, some progress has been realized. However, much more effort and insight will be required for further real gains to be made. We propose that studying the mTOR axis, known to be abnormal in non-small cell lung cancer (NSCLC), and translating that knowledge into therapeutic adjustments can lead to meaningful advances in lung cancer treatment.

Approximately 58 patients will participate at Emory Winship Cancer Institute and Emory Crawford W. Long Hospital in Atlanta, Georgia.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histologically confirmed non-small cell lung cancer (NSCLC) which is accessible to biopsy.
  • Patient must have ECOG Performance Status of 0, 1, or 2.
  • Life expectancy greater than 12 weeks.
  • Patient must have adequate bone marrow, renal and hepatic function as defined in the protocol.
  • Completed all prior therapy at least 3 weeks prior to registration and be adequately recovered from that therapy.
  • Must be at least 18 years of age.
  • Meet pre-entry requirements as specified in Section 7.0.
  • Female patients of child-bearing potential must have a negative serum pregnancy test prior to study entry.
  • Patients of child-bearing potential must agree to use an effective form of contraception while on study and for 3 months following completion of study treatment.
  • Patient must not have more than one prior chemotherapy regimen.
  • Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Exclusion Criteria:

  • Chronic treatment with systemic steroids or other immunosuppressive agents.
  • Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases.
  • A known history of HIV seropositivity.
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).
  • Patients with an active, bleeding diathesis or an oral anti-vitamin K medication (except low dose coumadin).
  • Known hypersensitivity to everolimus, sirolimus, or any of its excipients.
  • Patient is pregnant or breast-feeding.
  • Patient has intercurrent illness including, but not limited to: ongoing active or severe infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension, myocardial infarction within 6 months, uncontrolled diabetes mellitus, chronic liver or renal disease, active upper GI tract ulceration or psychiatric illness/social situations that would limit compliance with study requirements.
  • Patient is unable to swallow RAD001.
  • History of other invasive malignancies, with the exception of non-melanoma skin cancer, if there is any evidence of the malignancy being present within the past 5 years.
  • History of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. Symptoms may include any reaction such as bronchospasm, generalized urticaria, systolic BP ≤ 80mm Hg, and angioedema.
  • Patient has received treatment with an investigational agent within 4 weeks of registration.
  • Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00406276

Locations
United States, Georgia
Emory University Winship Cancer Institute
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Investigators
Principal Investigator: Suresh Ramalingam, MD Emory University Winship Cancer Institute
  More Information

No publications provided

Responsible Party: Suresh S. Ramalingam, MD, Emory University
ClinicalTrials.gov Identifier: NCT00406276     History of Changes
Other Study ID Numbers: 1342-2004
Study First Received: November 17, 2006
Results First Received: March 30, 2012
Last Updated: August 19, 2013
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by Emory University:
Lung Cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Docetaxel
Sirolimus
Everolimus
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 15, 2014